Regeneus achieves major milestones and secures critical Japan collaboration

John Martin, chief executive for Regeneus, speaks with Proactive Investors.

John Martin talks to Andrew Scott, Proactive Investors in London, discussing some of RGS' major achievements of FY17 in particular the critical Japanese collaboration with AGC, positive STEP Phase 1 results and IP protection for Progenza in Japan, which sets RGS up nicely for discussions with potential clinical partners.

Watch John's full video interview with Proactive Investors here.